Education
About Us
Working with TipRanks
Follow Us
Avita Medical (RCEL)
NASDAQ:RCEL
RCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.51 - $17.67
Previous CloseN/A
Volume824.49K
Average Volume (3M)185.34K
Market Cap
$230.89M
Enterprise Value$279.77M
Total Cash (Recent Filing)$124.82M
Total Debt (Recent Filing)$3.13M
Price to Earnings (P/E)―
Beta2.87
Next Earnings
May 08, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding26,357,542
10 Day Avg. Volume179,617
30 Day Avg. Volume185,335
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.58
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.71
Enterprise Value/Ebitda-5.21
Forecast
1Y Price Target
$16.20Price Target Upside84.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Avita Medical News
PremiumCompany Announcements
AVITA Medical Reports Transformative Year Amidst Challenges
PremiumCompany Announcements
AVITA Medical Reports Revenue Growth Amid New Product Approvals---
Bulls Say, Bears Say
Bulls Say
Product Portfolio ExpansionThe acquisition of Cohealyx, a collagen-based dermal matrix product, is expected to triple Avita's addressable market in burns.
Revenue GrowthAvita is forecasting remarkable revenue growth of 55-65%, a significant acceleration from previous performance, and has outlined plans to achieve key profitability metrics.
Bears Say
Valuation ConcernsCurrent valuation reflects a Neutral rating due to concerns about RCEL's ability to gain traction in the skin defect launch.
---
Ownership Overview
1.16% Insiders
8.52% Mutual Funds
1.56% Other Institutional Investors
79.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCEL FAQ
What was Avita Medical’s price range in the past 12 months?
Avita Medical lowest stock price was $7.51 and its highest was $17.67 in the past 12 months.
What is Avita Medical’s market cap?
Avita Medical’s market cap is $230.89M.
When is Avita Medical’s upcoming earnings report date?
Avita Medical’s upcoming earnings report date is May 08, 2025 which is in 63 days.
How were Avita Medical’s earnings last quarter?
Avita Medical released its earnings results on Feb 13, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.429 by -$0.011.
Is Avita Medical overvalued?
According to Wall Street analysts Avita Medical’s price is currently Undervalued.
Does Avita Medical pay dividends?
Avita Medical does not currently pay dividends.
What is Avita Medical’s EPS estimate?
Avita Medical’s EPS estimate is -0.32.
How many shares outstanding does Avita Medical have?
Avita Medical has 26,357,542 shares outstanding.
What happened to Avita Medical’s price movement after its last earnings report?
Avita Medical reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.429. Following the earnings report the stock price went up 20.387%.
Which hedge fund is a major shareholder of Avita Medical?
Among the largest hedge funds holding Avita Medical’s share is Hussman Strategic Advisors Inc. It holds Avita Medical’s shares valued at 0.
---
Avita Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.20 (84.93% Upside)
$16.20 (84.93% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $139.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.05%
12-Months-Change
Fundamentals
Return on Equity
-72.12%
Trailing 12-Months
Asset Growth
-28.60%
Trailing 12-Months
Company Description
Avita Medical
Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.
---
RCEL Company Deck
---
RCEL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
AVITA Medical's earnings call reflected a transformative year with substantial revenue growth, improved gross profit margins, and a significant increase in total addressable market due to new product launches. However, the company faced challenges with a Q4 revenue shortfall, increased net losses, and higher operating expenses, which balanced the positive achievements.Read More>---
RCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
---
RCEL Stock 12 Month Forecast
Average Price Target
$16.20
▲(84.93% Upside)
Technical Analysis
Best Analysts Covering RCEL
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-13.87%
reiterated a buy rating 17 days ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -13.87% per trade.
---